Prognostic Value of the Lung Immune Prognostic Index in Metastatic Renal Cell Carcinoma Treated With Second‑Line Immunotherapy
The Lung Immune Prognostic Index (LIPI) may better reflect immunotherapy‑related outcomes in this setting.
Prognostic stratification remains challenging in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors. The Lung Immune Prognostic Index (LIPI) may better reflect immunotherapy‑related outcomes in this setting.
The study shows that LIPI outperforms existing prognostic models (MSKCC and IMDC) in predicting overall survival for mRCC patients receiving second‑line nivolumab, thereby supporting its clinical utility for risk stratification.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)